Abstract
Pregnancy morbidity and vascular thrombosis provide the clinical manifestations of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of the treatment of obstetric APS. However, the debate is still open: controversies involve the management of rare aPL-mediated obstetric complications, the treatment of vascular manifestations, and the treatment of refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. In addition, no treatment trial has ever investigated the optimal treatment of aPL women stratifying upon the different risk profile (aPL profile, associated autoimmune disease, previous obstetrical history). The recommended therapeutic managements of different aPL-related obstetrical clinical manifestations are hereby presented, with a critical appraisal of the evidence supporting each approach.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Miyakis S, Lockshin MD, Atsumi M et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical, and immunologic manifestations and pattern of disease expression in a color of 1000 patients. Arthritis Rheum 46:1019–1027
Neville C, Rauch J, Kassis J et al (2009) Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost 101:100–107
Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8:237–242
Rai RS, Clifford K, Cohen H et al (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10:3301–3304
De Groot PG, Lutters B, Derksen RHWM et al (2004) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 3:1993–1997
Rai R, Regan L (1997) Obstetric complications of antiphospholipid antibodies. Curr Opin Obstet Gynecol 9:387–390
Ruffatti A, Del Ross T, Ciprian M et al (2009) Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicenter, retrospective follow-up study. Ann Rheum Dis 68:397–399
Ruiz-Irastorza G, Khamashta MA (2011) Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest 41:672–678
Danza A, Ruiz-Irastorza G, Khamashta MA (2012) Antiphospholipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 26:65–76
Le Thi Huong D, Wechsler B, Vauthier-Brouzes D et al (2006) The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 45:332–338
Cnossen JS, Morris RK, ter Riet G et al (2008) Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 178:701–711
Ruiz-Irastorza G, Khamashta MA (2007) Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 33:287–297
Empson M, Lassere M, Craig J et al (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. doi:10.1002/14651858.CD002859
Mak A, Cheung MW, Cheak AA et al (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing livebirths in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 49:281–288
Ziakas PD, Pavlou M, Voulgarelis M (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 115:1256–1262
Lubbe WF, Butler WS, Palmer SJ et al (1983) Foetal survival after prednisolone suppression of maternal lupus-anticoagulant. Lancet 18:1361–1363
Lockshin MD, Druzin ML, Qamar T (1989) Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 160:439–443
Elder MG, de Swiet M, Robertson A et al (1988) Low dose aspirin in pregnancy. Lancet 1:410
Carmona F, Font J, Azulay M et al (2001) Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 46:274–279
Silver RK, MacGregor SN, Sholl JS et al (1993) Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 169:1411–1417
Lima F, Khamashta MA, Buchanan NMM et al (1996) A study of sixty pregnancies patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14:131–136
Granger KA, Farquharson RG (1997) Obstetric outcome in antiphospholipid syndrome. Lupus 6:509–513
Huong DLT, Wechsler B, Bletry O et al (2001) A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 28:2025–2030
Munoz-Rodriguez FJ, Font J, Cervera R et al (1999) Clinical study of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 29:182–190
Pattison NS, Chamley LW, Birdsall M et al (2000) Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 183:1008–1012
Tulppala M, Marttunen M, Soderstrom-Anttila V et al (1997) Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 12:1567–1572
Rosove MH, Tabsh K, Wasserstrum N et al (1990) Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 75:630–634
Cowchock FS, Reece EA, Baldan D et al (1992) Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 166:1318–1327
Laskin CA, Bombardier C, Hannah ME et al (1997) Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 337:148–153
Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174:1584–1589
Rai R, Cohen H, Dave M et al (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314:253–257
Fishman P, Falach-Vaknin E, Sredni B et al (1996) Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 35:80–84
Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10:1222–1226
Di Simone N, Marana R, Castellani R et al (2010) Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 62:1504–1512
D’Ippolito S, Marana R, Di Nicuolo F et al (2012) Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)–mediated inhibition of endometrial angiogenesis. PLoS One. doi:10.1371/journal.pone.0029660
de Carvalho JF, de Oliveira RM, Rodrigues CEM et al (2012) Heparin increases HLA-G levels in primary antiphospholipid syndrome. Clin Dev Immunol. doi:10.1155/2012/232390
Bates SM, Greer IA, Pabinger I et al (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:844S–886S
Laskin CA, Spitzer KA, Clark CA et al (2009) Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 36:279–287
Stephenson MD, Ballem PJ, Tsang P et al (2004) Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 26:729–734
Noble LS, Kutteh WH, Lashey N et al (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83:684–690
Ensom MH, Stephenson MD (2004) Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig 11:377–383
Kutteh WH, Ermel LD (1996) A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 35:402–407
Ruffatti A, Gervasi MT, Favaro M et al (2011) Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Clin Exp Rheumatol 29:551–554
De Sancho MT, Khalid S, Christos PJ (2012) Outcomes in women receiving low-molecular weight heparin during pregnancy. Blood Coagul Fibrinolysis 23:51–755
Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330:565
Askie LM, Duley L, Henderson-Smart DJ, PARIS Collaborative Group et al (2007) Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet 369:1791–1798
Sinha J, Chowdhry I, Sedan S, Barland P (2002) Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol 29:195–197
Pauzner R, Dulitzky M, Carp H et al (2003) Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. J Thromb Haemost 1:1758–1763
Haram K, Trovik J, Sandset PM et al (2003) Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. Acta Obstet Gynecol Scand 82:679–680
Roberts G, Gordon MM, Porter D et al (2003) Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: successful outcome using plasma exchange therapy. Lupus 12:251–257
Ilbery M, Jones AR, Sampson MB, Samson J (1995) Lupus anticoagulant and HELLP syndrome complicated by placental abruption, hepatic, dermal and adrenal infarction. Aust N Z J Obstet Gynaecol 35:215–217
Alsulyman OM, Castro MA, Zuckerman E et al (1996) Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet Gynecol 88:644–646
Amant F, Spitz B, Arnout J, Van Assche FA (1997) Hepatic necrosis and haemorrhage in pregnant patients with antiphospholipid antibodies. Lupus 6:552–555
Alijotas-Reis J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17
Ruffatti A, Calligaro A, Hoxha A et al (2010) Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 62:302–307
Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64
Pauzner R, Dulitzki M, Langevitz P et al (2001) Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 86:1379–1384
Østensen M, Khamashta M, Lockshin M et al (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8:209
Lockshin MD (2013) Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy. Clin Lab Med 33:367–376
Erkan D, Patel S, Nuzzo M et al (2008) Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology 47:23–27
Carreras LO, Perez GN, Vega H et al (1988) Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 2:393–394
Parke A, Maier D, Wilson D et al (1989) Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 110:495–496
Scott JR, Branch DW, Kochenour NK et al (1989) Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 159:055–1056
Wapner RJ, Cowchock FS, Shapiro SS (1989) Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am J Obstet Gynecol 161:1271–1272
Ron-el R, Vinder A, Golan A et al (1993) The use of intravenous gammaglobulin, heparin and aspirin in the maintenance of a pregnancy of freeze thawed embryo in a patient with lupus anticoagulant. Eur J Obstet Gynecol Reprod Biol 52:131–133
Kaaja R, Julkunen H, Ammala P et al (1993) Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 72:63–66
Spinnato JA, Clark AL, Pierangeli SS et al (1995) Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 172:690–694
Valensise H, Vaquero E, De Carolis C et al (1995) Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diagn 15:509–517
Clark AL, Branch DW, Silver RM et al (1999) Pregnancy complicated by the antiphospolipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 93:437–441
Marzusch K, Dietl J, Klein R et al (1996) Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 75:922–926
Triolo G, Ferrante A, Accardo-Palumbo A et al (2004) IVIG in pregnancy. Lupus 13:731–735
Bramham K, Thomas M, Nelson-Piercy C et al (2011) First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117:6948–6951
Bontadi A, Ruffatti A, Tison T et al (2012) Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 27:200–204
Bortolati M, Marson P, Chiarelli S et al (2009) Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 13:157–160
Ruffatti A, Marson P, Pengo V et al (2007) Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6:196–202
Cowchock S, Reece EA (1997) Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol 176:1099–1100
Del Ross T, Ruffatti A, Visentin MS et al (2013) Treatment of 139 pregnancies in anti-phospholipid positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 40:425–429
Soh MC, Pasupathy D, Gray G et al (2013) Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. Rheumatology 52:1642–1647
Mekinian A, Loire-Berson P, Nicaise-Roland P et al (2012) Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 94:222–226
Gardiner C, Hills J, Machin SJ et al (2013) Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 22:18–25
Gris JC, Bouvier S, Molinari N et al (2012) Comparative incidence of a first thrombotic events in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-AOS observational study. Blood 119:2624–2632
Martinez-Zamora MA, Peralta S, Creus M et al (2012) Risk of thrombotic events after recurrent abortion in anti-phospholipid syndrome: a case-control study. Ann Rheum Dis 71:61–66
Horlocker T, Wedel D, Rowlingson J et al (2010) Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 35:64–101
Douketis JD, Berger P, Dunn A et al (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:299S–339S
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Acaia, B., Rossi, F., Chighizola, C.B. (2015). Treatment of Pregnancy Complications. In: Meroni, P. (eds) Antiphospholipid Antibody Syndrome. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-11044-8_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-11044-8_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-11043-1
Online ISBN: 978-3-319-11044-8
eBook Packages: MedicineMedicine (R0)